Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celldex Therapeutics, an integrated biopharmaceutical company, has signed an exclusive patent and know-how license agreement with the University of Southampton, UK, to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers.
Subscribe to our email newsletter
In preclinical models, antibodies to CD27 have been shown to mediate anti-tumor effects alone, and may be particularly effective in combination with other immunotherapies. Financial terms of the transaction were not disclosed.
Anthony Marucci, president and CEO of Celldex Therapeutics, said: “This antibody program brings more opportunity to our pipeline, and allows us to further demonstrate our development capabilities.
“We will continue to pursue additional partnerships with both biopharmaceutical companies and other academic institutions to exploit our ability to generate fully-human antibodies, and look forward to moving a number of programs into the clinic in the next few years.”